CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 68 enrolled
Drug / intervention
Ad4-EnvCN54 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03408262
NCT03408262Phase 1Completed
CompareCT.gov

A Phase I Single-Blind Randomised Trial Investigating Immunisation Strategies Using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA Combinations in Order to Maximise Antibody Responses to Human Immunodeficiency Virus

Imperial College London·interventional·Posted Jan 23, 2018·Updated Oct 16, 2024

In Brief

A Phase 1 clinical trial evaluating Ad4-EnvCN54, MVA-CN54, and 1 other intervention for Human Immunodeficiency Virus. Completed, enrolled 68 participants across 1 site.

Detailed Summary

A Phase I Single-Blind randomised trial investigating immunisation strategies using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA combinations in order to maximise antibody responses to Human Immunodeficiency Virus

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJan 23, 2018
Enrollment StartOct 6, 2017
Primary CompletionFeb 10, 2020
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8.4 years ago

Interventions

Ad4-EnvCN54biological

Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

MVA-CN54biological

Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

CN54gp140/MPLAbiological

Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant